Chiara Pozzato

Chiara Pozzato

Auto-generated profile, based on publicly available information

Chiara Pozzato

Institute of Pharmacology, University of Bern, 3010, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
CPChiara Pozzato
Chiara Pozzato
GOGonçalo Outeiro-Pinho
Gonçalo Outeiro-Pinho
MGMirco Galiè
Mirco Galiè
GRGiorgio Ramadori
Giorgio Ramadori
Georgia KonstantinidouGeorgia Konstantinidou
Georgia Konstantinidou
Mutated KRAS serves as the oncogenic driver in 30% of non-small cell lung cancers (NSCLCs) and is associated with metastatic and therapy-resistant tumors. Focal Adhesion Kinase (FAK) acts as a mediator in sustaining KRAS-driven lung tumors, and although FAK inhibitors are currently undergoing clinical development, clinical data indicated that their efficacy in producing long-term anti-tumor responses is limited. Here we revealed two FAK interactors, extracellular-signal-regulated kinase 5 (ERK5) and cyclin-dependent kinase 5 (CDK5), as key players underlying FAK-mediated maintenance of KRAS mutant NSCLC. Inhibition of ERK5 and CDK5 synergistically suppressed FAK function, decreased proliferation and induced apoptosis owing to exacerbated ROS-induced DNA damage. Accordingly, concomitant pharmacological inhibition of ERK5 and CDK5 in a mouse model of Kras G12D -driven lung adenocarcinoma suppressed tumor progression and promoted cancer cell death. Cancer cells resistant to FAK inhibitors showed enhanced ERK5-FAK signaling dampening DNA damage. Notably, ERK5 inhibition prevented the development of resistance to FAK inhibitors, significantly enhancing the efficacy of anti-tumor responses. Therefore, we propose ERK5 inhibition as a potential co-targeting strategy to counteract FAK inhibitor resistance in NSCLC.

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Various lines of investigation support a signaling interphase shared by receptor tyrosine kinases and the DNA damage response. However, the underlying network nodes and their contribution to the maintenance of DNA integrity remain unknown. We explored MET-related metabolic pathways in which interruption compromises proper resolution of DNA damage. Discovery metabolomics combined with transcriptomics identified changes in pathways relevant to DNA repair following MET inhibition (METi). METi by tepotinib was associated with the formation of γH2AX foci and with significant alterations in major metabolic circuits such as glycolysis, gluconeogenesis, and purine, pyrimidine, amino acid, and lipid metabolism. 5′-Phosphoribosyl-N-formylglycinamide, a de novo purine synthesis pathway metabolite, was consistently decreased in in vitro and in vivo MET-dependent models, and METi-related depletion of dNTPs was observed. METi instigated the downregulation of critical purine synthesis enzymes including phosphoribosylglycinamide formyltransferase, which catalyzes 5′-phosphoribosyl-N-formylglycinamide synthesis. Genes encoding these enzymes are regulated through E2F1, whose levels decrease upon METi in MET-driven cells and xenografts. Transient E2F1 overexpression prevented dNTP depletion and the concomitant METi-associated DNA damage in MET-driven cells. We conclude that DNA damage following METi results from dNTP reduction via downregulation of E2F1 and a consequent decline of de novo purine synthesis. Significance: Maintenance of genome stability prevents disease and affiliates with growth factor receptor tyrosine kinases. We identified de novo purine synthesis as a pathway in which key enzymatic players are regulated through MET receptor and whose depletion via MET targeting explains MET inhibition-associated formation of DNA double-strand breaks. The mechanistic importance of MET inhibition-dependent E2F1 downregulation for interference with DNA integrity has translational implications for MET-targeting-based treatment of malignancies.

17 September 2024
Verified
Other
Open access
PDF file
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Supplementations with glutamine, serine, and folic acid: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with glutamine, serine or folic acid. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 cells upon supplementation with glutamine, serine or folic acid.

17 September 2024
Verified
Other
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Various lines of investigation support a signaling interphase shared by receptor tyrosine kinases and the DNA damage response. However, the underlying network nodes and their contribution to the maintenance of DNA integrity remain unknown. We explored MET-related metabolic pathways in which interruption compromises proper resolution of DNA damage. Discovery metabolomics combined with transcriptomics identified changes in pathways relevant to DNA repair following MET inhibition (METi). METi by tepotinib was associated with the formation of γH2AX foci and with significant alterations in major metabolic circuits such as glycolysis, gluconeogenesis, and purine, pyrimidine, amino acid, and lipid metabolism. 5′-Phosphoribosyl-N-formylglycinamide, a de novo purine synthesis pathway metabolite, was consistently decreased in in vitro and in vivo MET-dependent models, and METi-related depletion of dNTPs was observed. METi instigated the downregulation of critical purine synthesis enzymes including phosphoribosylglycinamide formyltransferase, which catalyzes 5′-phosphoribosyl-N-formylglycinamide synthesis. Genes encoding these enzymes are regulated through E2F1, whose levels decrease upon METi in MET-driven cells and xenografts. Transient E2F1 overexpression prevented dNTP depletion and the concomitant METi-associated DNA damage in MET-driven cells. We conclude that DNA damage following METi results from dNTP reduction via downregulation of E2F1 and a consequent decline of de novo purine synthesis.Significance:Maintenance of genome stability prevents disease and affiliates with growth factor receptor tyrosine kinases. We identified de novo purine synthesis as a pathway in which key enzymatic players are regulated through MET receptor and whose depletion via MET targeting explains MET inhibition-associated formation of DNA double-strand breaks. The mechanistic importance of MET inhibition-dependent E2F1 downregulation for interference with DNA integrity has translational implications for MET-targeting-based treatment of malignancies.

17 September 2024
Verified
Other
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Summary of the significance analysis for the survival analyses.

17 September 2024
Verified
Other
Open access
PDF file
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
P4E-BP1 protein levels upon MET inhibition: Whole-cell lysates were subjected to Western blotting using a specific antibody against p4E-BP1 following the treatment either with vehicle or 50nM tepotinib (EMD1214063, shortly EMD) for either 4 or 24h as indicated. Western blots representative of N=3 independent experiments are shown.